David T. Rubin, MD
Dr Rubin reviews data from the QUASAR phase 3 trial of guselkumab in patients with ulcerative colitis, specifically looking at histologic remission, which he presented at the ACG Scientific Meeting in Nashville.
Dr Rubin reviews data from the QUASAR phase 3 trial of guselkumab in patients with ulcerative colitis, specifically looking at histologic remission, which he presented at the ACG Scientific Meeting in Nashville.
Dr Rubin reviews data from the...